Lixisenatide/insulin glargine: Additional Phase III data

Additional data from the open-label, international Phase III LixiLan-L trial in 736 Type II diabetics inadequately controlled on basal insulin with or without 1-2 oral anti-diabetic drugs showed that once-daily

Read the full 309 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE